SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 33075260.
- Also identified by DOI 10.7326/ACPJ202010200-040.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Liu J, Li L, Li S, et al. <b>Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.</b> Diabetes Obes Metab. 2020;22:1619-27. 32364674.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Ketoacidosis
- Sodium-Glucose Transporter 2 Inhibitors
- Symporters